FDA to consider safety of Tysabri today

A report by the FDA staff said they are concerned about Biogen Idec's safety plan for Tysabri if it is allowed back on the market as a treatment for multiple sclerosis, saying the drug could be prescribed to patients with "less severe forms of the disease" that might not justify the risks associated with Tysabri. An advisory panel will meet today to consider the return of the Biogen and Elan Corp. drug.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park